23 results for author:"Boross P." in Literature citations
Results Customize
› Repeat search in UniProtKB (9)
| FcgammaRIIb on myeloid cells and intrinsic renal cells rather than B cells protects from nephrotoxic nephritis. Sharp P.E., Martin-Ramirez J., Mangsbo S.M., Boross P., Pusey C.D., Touw I.P., Cook H.T., Verbeek J.S., Tarzi R.M. J. Immunol. 190:340-348(2013) · Mapped (6) |
| Fcgamma receptor IIb strongly regulates Fcgamma receptor-facilitated T cell activation by dendritic cells. van Montfoort N., 't Hoen P.A., Mangsbo S.M., Camps M.G., Boross P., Melief C.J., Ossendorp F., Verbeek J.S. J. Immunol. 189:92-101(2012) · Mapped (4) |
| Increased incidence of anti-GBM disease in Fcgamma receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone. Sharp P.E., Martin-Ramirez J., Boross P., Mangsbo S.M., Reynolds J., Moss J., Pusey C.D., Cook H.T., Tarzi R.M., Verbeek J.S. Mol. Immunol. 50:49-56(2012) · Mapped (8) |
| Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Tie Y., Wang Y.F., Boross P.I., Chiu T.Y., Ghosh A.K., Tozser J., Louis J.M., Harrison R.W., Weber I.T. Protein Sci. 21:339-350(2012) · UniProtKB (3) |
| The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility. Boross P., Arandhara V.L., Martin-Ramirez J., Santiago-Raber M.L., Carlucci F., Flierman R., van der Kaa J., Breukel C., Claassens J.W., Camps M. et al. J. Immunol. 187:1304-1313(2011) · Mapped (16) |
| In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. de Haij S., Jansen J.H., Boross P., Beurskens F.J., Bakema J.E., Bos D.L., Martens A., Verbeek J.S., Parren P.W., van de Winkel J.G. et al. Cancer Res. 70:3209-3217(2010) · Mapped (4) |
| Highly B lymphocyte-specific tamoxifen inducible transgene expression of CreER T2 by using the LC-1 locus BAC vector. Boross P., Breukel C., van Loo P.F., van der Kaa J., Claassens J.W., Bujard H., Schonig K., Verbeek J.S. Genesis 47:729-735(2009) · Mapped (3) |
| Destructive arthritis in the absence of both FcgammaRI and FcgammaRIII. Boross P., van Lent P.L., Martin-Ramirez J., van der Kaa J., Mulder M.H., Claassens J.W., van den Berg W.B., Arandhara V.L., Verbeek J.S. J. Immunol. 180:5083-5091(2008) · Mapped (15) |
| Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. Wang Y.F., Tie Y., Boross P.I., Tozser J., Ghosh A.K., Harrison R.W., Weber I.T. J. Med. Chem. 50:4509-4515(2007) · Mapped (1) |
| Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Tie Y., Kovalevsky A.Y., Boross P., Wang Y.F., Ghosh A.K., Tozser J., Harrison R.W., Weber I.T. |
| Effect of immune serum and role of individual Fcgamma receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine macrophages. Uppington H., Menager N., Boross P., Wood J., Sheppard M., Verbeek S., Mastroeni P. Immunology 119:147-158(2006) · Mapped (20) |
| Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition. Fang B., Boross P.I., Tozser J., Weber I.T. J. Mol. Biol. 360:654-666(2006) · Mapped (2) |
| Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. Feher A., Boross P., Sperka T., Miklossy G., Kadas J., Bagossi P., Oroszlan S., Weber I.T., Tozser J. J. Gen. Virol. 87:1321-1330(2006) · UniProtKB (2) |
| Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. Liu F., Kovalevsky A.Y., Louis J.M., Boross P.I., Wang Y.F., Harrison R.W., Weber I.T. J. Mol. Biol. 358:1191-1199(2006) · Mapped (1) |
| Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. Kovalevsky A.Y., Tie Y., Liu F., Boross P.I., Wang Y.F., Leshchenko S., Ghosh A.K., Harrison R.W., Weber I.T. J. Med. Chem. 49:1379-1387(2006) · Mapped (1) |
| Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. Liu F., Boross P.I., Wang Y.F., Tozser J., Louis J.M., Harrison R.W., Weber I.T. J. Mol. Biol. 354:789-800(2005) · Mapped (2) |
| Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. Tie Y., Boross P.I., Wang Y.F., Gaddis L., Liu F., Chen X., Tozser J., Harrison R.W., Weber I.T. FEBS J. 272:5265-5277(2005) · Mapped (1) |
| Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease. Kadas J., Weber I.T., Bagossi P., Miklossy G., Boross P., Oroszlan S., Toezser J. J. Biol. Chem. 279:27148-27157(2004) · UniProtKB (2) |
| High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. Tie Y., Boross P.I., Wang Y.-F., Gaddis L., Hussain A.K., Leshchenko S., Ghosh A.K., Louis J.M., Harrison R.W., Weber I.T. J. Mol. Biol. 338:341-352(2004) · UniProtKB (1) · Mapped (1) |
| Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Mahalingam B., Wang Y.-F., Boross P.I., Tozser J., Louis J.M., Harrison R.W., Weber I.T. Eur. J. Biochem. 271:1516-1524(2004) · UniProtKB (1) |
| Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Koh Y., Nakata H., Maeda K., Ogata H., Bilcer G., Devasamudram T., Kincaid J.F., Boross P., Wang Y.F., Tie Y. et al. Antimicrob. Agents Chemother. 47:3123-3129(2003) · Mapped (1) |
| Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis. Nabbe K.C., Blom A.B., Holthuysen A.E., Boross P., Roth J., Verbeek S., van Lent P.L., van den Berg W.B. Arthritis Rheum. 48:255-265(2003) · Mapped (12) |
| Combining mutations in HIV-1 protease to understand mechanisms of resistance. Mahalingam B., Boross P.I., Wang Y.-F., Louis J.M., Fischer C.C., Tozser J., Harrison R.W., Weber I.T. Proteins 48:107-116(2002) · UniProtKB (1) |